A single dose of a synthetic, proprietary formulation of psilocybin (COMP360) was found to improve symptoms in patients with treatment-resistant depression (TRD), according to phase 3 trial results.

Psilocybin-based therapies are nearing FDA review, raising hopes and concerns about safety, scalability, and the therapy’s ...

Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 The ...

(The Center Square) – Mental health care providers are rediscovering new uses for old medicines. Recent findings demonstrating the efficacy of psilocybin, the active ingredient in magic mushrooms, ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...

Screening closed for all sites and final participants being scheduled for dosing On track for top-line 6-week primary endpoint results in late Q2 LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways ...

INDIANAPOLIS (WISH) — Mental health struggles impact more than 60 million Americans every year. In 2023, 105,000 lives were lost to drug overdoses and thousands more to suicide. For many, traditional ...